Another Notable Development Hyperfine's track record of securing international approvals supports its expansion into global markets. Along with the latest expansion in the European market, the company also announced a distribution agreement to develop Asian markets. Estimates for Medpace's 2024 EPS have remained unchanged at $11.29 in the past 30 days. Shares of the company have soared 73.3% in the past year compared with the industry's 5.2% growth. With the recent addition of distributors and the previousl ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________ FORM 10-Q _________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________to_________ Commission File Number: 001-39949 Hyperfine, Inc. (Exact name of registrant as specified in its cha ...

财务数据和关键指标变化 - 2024年第一季度收入为3.3亿美元,同比增长25%,主要由于销售了13台Swoop系统 [24] - 2024年第一季度毛利为1.4亿美元,毛利率为41.1% [25] - 2024年第一季度净亏损为9.8亿美元,每股亏损0.14美元,同比亏损减少 [26] - 公司维持2024年全年收入指引为12亿美元至15亿美元,毛利率预计在45%至50%之间 [27] - 公司预计2024年全年现金消耗约为4亿美元,现金储备可持续到2026年初 [26][27] 各条业务线数据和关键指标变化 - 公司在美国继续增加旗舰医疗机构用户,最近新增华盛顿特区的MedStar华盛顿医院中心 [19] - 公司在国际市场建立了分销基础设施,已在欧洲三个主要市场任命了分销商 [21] 各个市场数据和关键指标变化 - 国际市场销售占比较高,导致平均销售价格有所下降 [24][36][37][38][39] - 公司正在考虑在德国等其他大型医疗技术市场寻找合适的分销商合作伙伴 [38][39] 公司战略和发展方向及行业竞争 - 公司专注于创新、临床证据和商业化,以推动2025年及以后的业务加速增长 [22] - 公司持续投资硬件、软件和人工智能等创新领域,计划在今年夏末推出下一代AI驱动的软件 [11][12] - 公司正在开展急性卒中和阿尔茨海默病等临床研究,以拓展Swoop系统在新的临床应用和护理场景的使用 [13][14][15][16][17][18] - 公司正在建立Swoop用户社区,分享最佳实践,以推动这项变革性技术的进一步采用 [20] 管理层对经营环境和未来前景的评论 - 公司对2024年的表现感到满意,团队在创新、临床和商业化方面都取得了出色的成果 [10][22] - 公司看好Swoop系统在急性卒中和阿尔茨海默病等大型市场的应用前景 [15][16] - 公司对国际市场的发展前景保持乐观,正在积极拓展分销渠道 [38][39] - 公司将继续保持谨慎的支出纪律,同时投资于未来增长动力 [25][26][27] 问答环节重要的提问和回答 问题1 **Xuyang Li 提问** 询问国际市场销售价格和销量情况 [49][50][51][52][53] **Maria Sainz 回答** 公司在美国市场的销售价格保持强劲,但国际市场销售价格较低,导致整体平均销售价格有所下降。公司正在积极拓展国际分销渠道,但仍存在一定的交易时间不确定性。[53][54] 问题2 **Unidentified Analyst 提问** 询问为何不提高收入指引下限 [33][34] **Marissa Bych 回答** 公司发布收入指引才7周,目前仍保持谨慎,不想过于乐观。随着国际业务的拓展,未来有机会提高指引区间 [34] 问题3 **Unidentified Analyst 提问** 询问新出台的人工智能法规对Swoop系统的影响 [46][47] **Maria Sainz 回答** 公司的深度学习算法都是自主研发的,不使用外部算法,主要用于图像降噪和重建,暂时没有发现新法规会对公司产生影响,但会进一步核实确认 [47]

Hyperfine, Inc. (HYPR) came out with a quarterly loss of $0.14 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.17 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this company would post a loss of $0.17 per share when it actually produced a loss of $0.15, delivering a surprise of 11.76%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. Hyperfine, which belongs to the Zacks M ...

Exhibit 99.1 Hyperfine, Inc. Reports First Quarter 2024 Financial Results GUILFORD, Connecticut, May 13, 2024 (GLOBE NEWSWIRE) – Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced first quarter 2024 financial results and provided a business update. "We have kicked off 2024 strong. I am pleased with our commercial progress shown by sales ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Hyperfine, Inc. (HYPR) reports results for the quarter ended March 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on May 13, 2024, might help the stock move higher if these key numbers are better than exp ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Commission file number: 001-39949 Hyperfine, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 98-1569027 (I.R.S. Employer Identification No.) 351 New Whitfield Street Guilford, Connecticut 06437 (Address o ...

Marissa Bych - Gilmartin Group, Investor Relations Maria Sainz - President and Chief Executive Officer Brett Hale - Chief Administrative Officer and Chief Financial Officer Conference Call Participants Before we begin, I would like to remind you that management will make statements during this call that include forward-looking statements within the meaning of Federal Securities laws, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements ...

Hyperfine, Inc. (NASDAQ:HYPR) Q3 2023 Earnings Call November 9, 2023 4:30 PM ET Operator Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of Federal Securities laws, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions of future events, results or performance are forwa ...

The Swoop system expands the fast growing (6% annual CAGR) $35 billion global imaging market. CONFIDENTIAL – PROPERTY OF HYPERFINE, INC. ©2023, All rights reserved. 10 Deep Foundation to Drive Long-term Success Rapid Innovation Clinical Proof Regulatory Excellence Ecosystem of Support 11 A First for Brain Health | --- | --- | |---------------------|----------------------------------------------------| | | | | | | | Hyperfine, Inc. has | | | 01 | reimagined brain imaging | | with the | Swoop system — | | | a ...